{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:31:44Z","timestamp":1794853904368,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7769","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2019,8,15]]},"DOI":"10.1038\/s41586-019-1426-6","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T14:02:31Z","timestamp":1563976951000},"page":"402-406","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1052,"title":["Intercellular interaction dictates cancer cell ferroptosis via NF2\u2013YAP signalling"],"prefix":"10.1038","volume":"572","author":[{"given":"Jiao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Minikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent R.","family":"Stockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"1426_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171, 273\u2013285 (2017).","journal-title":"Cell"},{"key":"1426_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ceb.2017.11.001","volume":"51","author":"M Gao","year":"2018","unstructured":"Gao, M. & Jiang, X. To eat or not to eat\u2014the metabolic flavor of ferroptosis. Curr. Opin. Cell Biol. 51, 58\u201364 (2018).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1426_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317\u2013331 (2014).","journal-title":"Cell"},{"key":"1426_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molcel.2018.10.042","volume":"73","author":"M Gao","year":"2019","unstructured":"Gao, M. et al. Role of mitochondria in ferroptosis. Mol. Cell 73, 354\u2013363.e3 (2019).","journal-title":"Mol. Cell"},{"key":"1426_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57\u201362 (2015).","journal-title":"Nature"},{"key":"1426_CR6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1101\/gad.275891.115","volume":"30","author":"M Jennis","year":"2016","unstructured":"Jennis, M. et al. An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 30, 918\u2013930 (2016).","journal-title":"Genes Dev."},{"key":"1426_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol. 20, 1181\u20131192 (2018).","journal-title":"Nat. Cell Biol."},{"key":"1426_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453\u2013457 (2017).","journal-title":"Nature"},{"key":"1426_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247\u2013250 (2017).","journal-title":"Nature"},{"key":"1426_CR10","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"1426_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"1426_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cmet.2008.07.005","volume":"8","author":"A Seiler","year":"2008","unstructured":"Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12\/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8, 237\u2013248 (2008).","journal-title":"Cell Metab."},{"key":"1426_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1593\/neo.91782","volume":"12","author":"M Schneider","year":"2010","unstructured":"Schneider, M. et al. Absence of glutathione peroxidase 4 affects tumor angiogenesis through increased 12\/15-lipoxygenase activity. Neoplasia 12, 254\u2013263 (2010).","journal-title":"Neoplasia"},{"key":"1426_CR14","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","volume":"59","author":"M Gao","year":"2015","unstructured":"Gao, M., Monian, P., Quadri, N., Ramasamy, R. & Jiang, X. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298\u2013308 (2015).","journal-title":"Mol. Cell"},{"key":"1426_CR15","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1007\/s00018-008-8281-1","volume":"65","author":"F van Roy","year":"2008","unstructured":"van Roy, F. & Berx, G. The cell\u2013cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 65, 3756\u20133788 (2008).","journal-title":"Cell. Mol. Life Sci."},{"key":"1426_CR16","doi-asserted-by":"publisher","first-page":"11930","DOI":"10.1073\/pnas.1103345108","volume":"108","author":"NG Kim","year":"2011","unstructured":"Kim, N. G., Koh, E., Chen, X. & Gumbiner, B. M. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc. Natl Acad. Sci. USA 108, 11930\u201311935 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1426_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1083\/jcb.200503165","volume":"171","author":"T Okada","year":"2005","unstructured":"Okada, T., Lopez-Lago, M. & Giancotti, F. G. Merlin\/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J. Cell Biol. 171, 361\u2013371 (2005).","journal-title":"J. Cell Biol."},{"key":"1426_CR18","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ceb.2008.10.001","volume":"20","author":"B Zhao","year":"2008","unstructured":"Zhao, B., Lei, Q. Y. & Guan, K. L. The Hippo\u2013YAP pathway: new connections between regulation of n size and cancer. Curr. Opin. Cell Biol. 20, 638\u2013646 (2008).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1426_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","volume":"19","author":"D Pan","year":"2010","unstructured":"Pan, D. The Hippo signaling pathway in development and cancer. Dev. Cell 19, 491\u2013505 (2010).","journal-title":"Dev. Cell"},{"key":"1426_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/embor.2012.11","volume":"13","author":"W Li","year":"2012","unstructured":"Li, W., Cooper, J., Karajannis, M. A. & Giancotti, F. G. Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep. 13, 204\u2013215 (2012).","journal-title":"EMBO Rep."},{"key":"1426_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","volume":"26","author":"W Li","year":"2014","unstructured":"Li, W. et al. Merlin\/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 26, 48\u201360 (2014).","journal-title":"Cancer Cell"},{"key":"1426_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10137","volume":"474","author":"S Dupont","year":"2011","unstructured":"Dupont, S. et al. Role of YAP\/TAZ in mechanotransduction. Nature 474, 179\u2013183 (2011).","journal-title":"Nature"},{"key":"1426_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<620::AID-IJC21>3.0.CO;2-B","volume":"75","author":"MH Falk","year":"1998","unstructured":"Falk, M. H. et al. Apoptosis in Burkitt lymphoma cells is prevented by promotion of cysteine uptake. Int. J. Cancer 75, 620\u2013625 (1998).","journal-title":"Int. J. Cancer"},{"key":"1426_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tcb.2011.10.002","volume":"22","author":"X Varelas","year":"2012","unstructured":"Varelas, X. & Wrana, J. L. Coordinating developmental signaling: novel roles for the Hippo pathway. Trends Cell Biol. 22, 88\u201396 (2012).","journal-title":"Trends Cell Biol."},{"key":"1426_CR25","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1101\/gad.1602907","volume":"21","author":"B Zhao","year":"2007","unstructured":"Zhao, B. et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21, 2747\u20132761 (2007).","journal-title":"Genes Dev."},{"key":"1426_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91\u201398 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"1426_CR27","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chembiol.2019.01.008","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem. Biol. 26, 623\u2013633.e9 (2019).","journal-title":"Cell Chem. Biol."},{"key":"1426_CR28","doi-asserted-by":"publisher","first-page":"e02523","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon, S. J. et al. Pharmacological inhibition of cystine\u2013glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523 (2014).","journal-title":"eLife"},{"key":"1426_CR29","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","volume":"5","author":"S Dubey","year":"2010","unstructured":"Dubey, S. et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J. Thorac. Oncol. 5, 1655\u20131661 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"1426_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","volume":"8","author":"S Papa","year":"2013","unstructured":"Papa, S. et al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J. Thorac. Oncol. 8, 783\u2013787 (2013).","journal-title":"J. Thorac. Oncol."}],"updated-by":[{"DOI":"10.1038\/s41586-019-1480-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1426-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T04:10:50Z","timestamp":1732767050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1426-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":30,"journal-issue":{"issue":"7769","published-print":{"date-parts":[[2019,8,15]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1038\/s41586-019-1426-6","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"7 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An Amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.R.S. holds equity in and serves as a consultant to Inzen Therapeutics, consults with GLG and Guidepoint Global, and is an inventor on patents and patent applications related to IKE and ferroptosis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}